These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17637271)

  • 1. [Effects of angiotensin II type 1 receptor blocker on islet of diabetic db/db mice].
    Shao JQ; Iwashita N; Du H; Wang YY; Zhao M; Wang J; Watada H; Kawamori R
    Zhonghua Nei Ke Za Zhi; 2007 Apr; 46(4):306-10. PubMed ID: 17637271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II receptor blocker provides pancreatic beta-cell protection independent of blood pressure lowering in diabetic db/db mice.
    Shao JQ; Iwashita N; Du H; Wang YT; Wang YY; Zhao M; Wang J; Watada H; Kawamori R
    Acta Pharmacol Sin; 2007 Feb; 28(2):246-57. PubMed ID: 17241528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on beta-cell function and morphology in db/db mice.
    Shao J; Iwashita N; Ikeda F; Ogihara T; Uchida T; Shimizu T; Uchino H; Hirose T; Kawamori R; Watada H
    Biochem Biophys Res Commun; 2006 Jun; 344(4):1224-33. PubMed ID: 16650382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute treatment with candesartan cilexetil, an angiotensin II type 1 receptor blocker, improves insulin sensitivity in high-fructose-diet-fed rats.
    Li P; Koike T; Jiang HY; Wang ZH; Kawata Y; Oshida Y
    Horm Metab Res; 2012 Apr; 44(4):286-90. PubMed ID: 22344624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies.
    Liu H; Kitazato KT; Uno M; Yagi K; Kanematsu Y; Tamura T; Tada Y; Kinouchi T; Nagahiro S
    J Hypertens; 2008 Jul; 26(7):1435-45. PubMed ID: 18551021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of angiotensin II AT1 receptor inhibition and exercise training on insulin action in rats on high-fat diet.
    Wang Z; Koike T; Li P; Jiang H; Natsume Y; Mu L; Chen T; Oshida Y
    Life Sci; 2012 Feb; 90(9-10):322-7. PubMed ID: 22210187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy.
    Haneda M; Kikkawa R; Sakai H; Kawamori R;
    Diabetes Res Clin Pract; 2004 Oct; 66(1):87-95. PubMed ID: 15364166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II Type 1 receptor antagonism mediates uncoupling protein 2-driven oxidative stress and ameliorates pancreatic islet beta-cell function in young Type 2 diabetic mice.
    Chu KY; Leung PS
    Antioxid Redox Signal; 2007 Jul; 9(7):869-78. PubMed ID: 17508912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amelioration of cognitive impairment in the type-2 diabetic mouse by the angiotensin II type-1 receptor blocker candesartan.
    Tsukuda K; Mogi M; Li JM; Iwanami J; Min LJ; Sakata A; Fujita T; Iwai M; Horiuchi M
    Hypertension; 2007 Dec; 50(6):1099-105. PubMed ID: 17968000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET.
    Philipp T; Martinez F; Geiger H; Moulin B; Mourad G; Schmieder R; Lièvre M; Heemann U; Legendre C
    Nephrol Dial Transplant; 2010 Mar; 25(3):967-76. PubMed ID: 19887503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice.
    Fan Q; Liao J; Kobayashi M; Yamashita M; Gu L; Gohda T; Suzuki Y; Wang LN; Horikoshi S; Tomino Y
    Nephrol Dial Transplant; 2004 Dec; 19(12):3012-20. PubMed ID: 15574998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.
    Liao J; Kobayashi M; Kanamuru Y; Nakamura S; Makita Y; Funabiki K; Horikoshi S; Tomino Y
    J Nephrol; 2003; 16(6):841-9. PubMed ID: 14736011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Candesartan: widening indications for this angiotensin II receptor blocker?
    Mendis B; Page SR
    Expert Opin Pharmacother; 2009 Aug; 10(12):1995-2007. PubMed ID: 19563275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
    Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary oxidative stress markers closely reflect the efficacy of candesartan treatment for diabetic nephropathy.
    Yoshida S; Hashimoto T; Kihara M; Imai N; Yasuzaki H; Nomura K; Kiuchi Y; Tamura K; Ishigami T; Hirawa N; Toya Y; Kitamura H; Umemura S
    Nephron Exp Nephrol; 2009; 111(1):e20-30. PubMed ID: 19052474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
    Baumgart P; Reismann J; Pohlmeyer H; Düsing R
    Dtsch Med Wochenschr; 2001 May; 126(19):547-50. PubMed ID: 11402910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of Telmisartan and Linagliptin Preserves Pancreatic Islet Cell Function and Morphology in db/db Mice.
    Zhao S; Chan LK; Chen L; Cheng TW; Klein T; Leung PS
    Pancreas; 2016 Apr; 45(4):584-92. PubMed ID: 26495783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure.
    White M; Lepage S; Lavoie J; De Denus S; Leblanc MH; Gossard D; Whittom L; Racine N; Ducharme A; Dabouz F; Rouleau JL; Touyz R
    J Card Fail; 2007 Mar; 13(2):86-94. PubMed ID: 17395047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria.
    Fogari R; Corradi L; Zoppi A; Lazzari P; Mugellini A; Preti P; Rinaldi A
    Am J Hypertens; 2007 Oct; 20(10):1092-6. PubMed ID: 17903693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Candesartan cilexetil: an update.
    Joost A; Schunkert H; Radke PW
    Expert Opin Pharmacother; 2011 Aug; 12(11):1769-80. PubMed ID: 21651457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.